Vanguard Group’s G1 Therapeutics GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-2,491,109
Closed -$5.68M – 4396
2024
Q2
$5.68M Buy
2,491,109
+409,536
+20% +$1.56M ﹤0.01% 3204
2024
Q1
$8.99M Buy
2,081,573
+99,900
+5% +$348K ﹤0.01% 3021
2023
Q4
$6.04M Buy
1,981,673
+31,605
+2% +$59.4K ﹤0.01% 3207
2023
Q3
$2.81M Hold
1,950,068
– – ﹤0.01% 3477
2023
Q2
$4.86M Sell
1,950,068
-40,707
-2% -$111K ﹤0.01% 3316
2023
Q1
$5.34M Buy
1,990,775
+64,930
+3% +$312K ﹤0.01% 3279
2022
Q4
$10.5M Buy
1,925,845
+239,392
+14% +$2.01M ﹤0.01% 2930
2022
Q3
$21.1M Buy
1,686,453
+65,952
+4% +$753K ﹤0.01% 2598
2022
Q2
$8.01M Sell
1,620,501
-303,203
-16% -$1.68M ﹤0.01% 3106
2022
Q1
$14.6M Sell
1,923,704
-620,661
-24% -$5.89M ﹤0.01% 2948
2021
Q4
$26M Buy
2,544,365
+38,297
+2% +$488K ﹤0.01% 2699
2021
Q3
$33.6M Buy
2,506,068
+3,242
+0.1% +$52.8K ﹤0.01% 2580
2021
Q2
$54.9M Buy
2,502,826
+61,841
+3% +$1.37M ﹤0.01% 2318
2021
Q1
$58.7M Buy
2,440,985
+345,258
+16% +$8.02M ﹤0.01% 2230
2020
Q4
$37.7M Buy
2,095,727
+76,307
+4% +$1.14M ﹤0.01% 2345
2020
Q3
$23.3M Sell
2,019,420
-37,791
-2% -$624K ﹤0.01% 2386
2020
Q2
$49.9M Buy
2,057,211
+8,124
+0.4% +$134K ﹤0.01% 2015
2020
Q1
$22.6M Buy
2,049,087
+35,522
+2% +$663K ﹤0.01% 2229
2019
Q4
$53.2M Buy
2,013,565
+21,222
+1% +$496K ﹤0.01% 2082
2019
Q3
$45.4M Buy
1,992,343
+15,728
+0.8% +$496K ﹤0.01% 2116
2019
Q2
$60.6M Buy
1,976,615
+100,523
+5% +$2.12M ﹤0.01% 1998
2019
Q1
$31.1M Buy
1,876,092
+176,440
+10% +$3.35M ﹤0.01% 2304
2018
Q4
$32.5M Sell
1,699,652
-18,081
-1% -$677K ﹤0.01% 2232
2018
Q3
$89.8M Buy
1,717,733
+743,596
+76% +$40.5M ﹤0.01% 1865
2018
Q2
$42.3M Sell
974,137
-30,694
-3% -$1.32M ﹤0.01% 2209
2018
Q1
$37.2M Buy
1,004,831
+236,363
+31% +$6.31M ﹤0.01% 2219
2017
Q4
$15.2M Buy
768,468
+528,757
+221% +$11.4M ﹤0.01% 2615
2017
Q3
$5.97M Buy
239,711
+165,711
+224% +$3.06M ﹤0.01% 3046
2017
Q2
$1.29M Buy
+74,000
New +$1.29M ﹤0.01% 3514

Vanguard Group's GTHX Position: Q3 2024 in Review

Vanguard Group sold out of G1 Therapeutics (GTHX) in Q3 2024, closing a stake of 2,491,109 shares — an estimated $5.68M sold.

Vanguard Group first reported a position in GTHX in Q2 2017 and held it in 29 quarters. The position peaked at $89.8M in Q3 2018. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Vanguard Group reported no remaining G1 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Vanguard Group sold 2,491,109 G1 Therapeutics shares in Q3 2024, an estimated $5.68M.
  • Vanguard Group first reported a position in G1 Therapeutics in Q2 2017 and held it in 29 quarters.
  • Vanguard Group's G1 Therapeutics position peaked at $89.8M in Q3 2018.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics as of Q3 2024.

Based on Vanguard Group's 13F filing for Q3 2024, filed 13 Nov 2024.